Dr. Kruse on How to Converse About Biosimilars in Breast Cancer


Megan Kruse, MD, discusses how to converse with patients with breast cancer about implementing biosimilars in treatment.

Megan Kruse, MD, associate staff of breast medical oncology, Cleveland Clinic, discusses how to converse with patients with breast cancer about implementing biosimilars in treatment.

The use of biosimilars in breast cancer will continue to expand over the next few years, explains Kruse. There are many benefits to having a few treatment options that may have different costs or administration schedules but the same efficacy as the original drugs, says Kruse.

However, there are challenges with talking to patients about biosimilars because many of them want the original drugs that are known to be effective in very large studies which are associated with clinical benefit, according to Kruse. The concept of biosimilars is difficult to explain to patients; however, when biosimilars are compared with other medications, not necessarily used in oncology medicine, then they become more appealing. In the short term, physicians are learning how to implement these changes in clinical practice and how to standardize use in large hospital systems, concludes Kruse.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD